WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015036512) PHARMACEUTICAL COMPOSITIONS CONTAINING REFAMETINIB
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/036512    International Application No.:    PCT/EP2014/069453
Publication Date: 19.03.2015 International Filing Date: 11.09.2014
IPC:
A61K 9/28 (2006.01), A61K 31/18 (2006.01), A61K 9/16 (2006.01), A61K 9/20 (2006.01)
Applicants: BAYER PHARMA AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 178 13353 Berlin (DE)
Inventors: STROYER, Anke; (DE).
SKRABS, Susanne; (DE).
FORMELL, Michael; (DE).
WINTER, Gabriele; (DE).
KISSENBECK, Rosemarie; (DE)
Agent: BIP PATENTS; Bayer Intellectual Property GmbH Alfred-Nobel-Str. 10 40789 Monheim am Rhein (DE)
Priority Data:
13184229.6 13.09.2013 EP
13184539.8 16.09.2013 EP
Title (EN) PHARMACEUTICAL COMPOSITIONS CONTAINING REFAMETINIB
(FR) COMPOSITIONS PHARMACEUTIQUES CONTENANT DU RÉFAMÉTINIB
Abstract: front page image
(EN)The present invention relates to pharmaceutical compositions which contain refametinib, a hydrate, solvate, meta bolite or pharmaceutically acceptable salt thereof or a polymorph thereof, and which are coated with a stability-maintaining coating, to processes of preparing such compositions, and to uses of such compositions for treating hyper-proliferative disorders and/or angiogenesis disorders, such as cancer, either as a sole agent or in com bination with other anti-cancer therapies.
(FR)La présente invention concerne des compositions pharmaceutiques contenant du réfamétinib, un hydrate, un solvate, un métabolite ou un sel pharmaceutiquement acceptable de celui-ci ou, encore, un polymorphe de ceux-ci, lesdites compositions étant recouvertes d'un enrobage préservant leur stabilité. L'invention concerne également des procédés de préparation desdites compositions et leurs utilisations pour traiter affections hyperprolifératives et/ou angiogenèse anormale et, notamment le cancer, soit en tant qu'agent unique, soit en combinaison avec d'autres thérapies anticancéreuses.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)